Abstract
Advances in the understanding of Alzheimers disease (AD) pathogenesis provide strong support for a modified version of the amyloid cascade hypothesis, which is now often referred to as the amyloid β protein (Aβ) cascade hypothesis. The basic tenant of this modified hypothesis is that Aβ aggregates trigger a complex pathological cascade leading to neurodegeneration. Thus, as opposed to the original amyloid hypothesis, whose basic tenant was that amyloid deposits cause AD, the Aβ hypothesis is more inclusive in that it takes into account the possibility that several different Aβ assemblies might contribute to AD pathogenesis and not merely the detectable amyloid deposits within the brain. Significantly, the Aβ hypothesis has provided the rationale for a plethora of therapeutic interventions that target Aβ production, aggregation or clearance. Indeed, AD research is entering an exciting phase in which strategies derived from basic research will be tested in humans. Despite this progress, many aspects of AD pathogenesis, particularly those downstream of Aβ accumulation are not well understood. Herein, we explore several observations that serve to illustrate the more enigmatic aspects of the Aβ hypothesis, and discuss why further basic research may be critical in order to develop therapies designed to halt neurodegeneration and reverse cognitive decline in patients already suffering from AD dementia.
Keywords: dementia, amyloid protein precursor (APP), apolipoprotein E (APOE), pathological aging (PA), NSAIDs
Current Alzheimer Research
Title: Filling the Gaps in the Aβ Cascade Hypothesis of Alzheimers Disease
Volume: 3 Issue: 5
Author(s): Todd E. Golde, Dennis Dickson and Michael Hutton
Affiliation:
Keywords: dementia, amyloid protein precursor (APP), apolipoprotein E (APOE), pathological aging (PA), NSAIDs
Abstract: Advances in the understanding of Alzheimers disease (AD) pathogenesis provide strong support for a modified version of the amyloid cascade hypothesis, which is now often referred to as the amyloid β protein (Aβ) cascade hypothesis. The basic tenant of this modified hypothesis is that Aβ aggregates trigger a complex pathological cascade leading to neurodegeneration. Thus, as opposed to the original amyloid hypothesis, whose basic tenant was that amyloid deposits cause AD, the Aβ hypothesis is more inclusive in that it takes into account the possibility that several different Aβ assemblies might contribute to AD pathogenesis and not merely the detectable amyloid deposits within the brain. Significantly, the Aβ hypothesis has provided the rationale for a plethora of therapeutic interventions that target Aβ production, aggregation or clearance. Indeed, AD research is entering an exciting phase in which strategies derived from basic research will be tested in humans. Despite this progress, many aspects of AD pathogenesis, particularly those downstream of Aβ accumulation are not well understood. Herein, we explore several observations that serve to illustrate the more enigmatic aspects of the Aβ hypothesis, and discuss why further basic research may be critical in order to develop therapies designed to halt neurodegeneration and reverse cognitive decline in patients already suffering from AD dementia.
Export Options
About this article
Cite this article as:
Golde E. Todd, Dickson Dennis and Hutton Michael, Filling the Gaps in the Aβ Cascade Hypothesis of Alzheimers Disease, Current Alzheimer Research 2006; 3 (5) . https://dx.doi.org/10.2174/156720506779025189
DOI https://dx.doi.org/10.2174/156720506779025189 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vascular Endothelial Growth Factor: Adaptive Changes in the Neuroglialvascular Unit
Current Neurovascular Research Smart Community Care System: Ambient Intelligence Using Radio Frequency Identification (RFID) and Mobile Agent
Recent Patents on Computer Science Effect of Cholinergic Stimulation in Early Alzheimers Disease - Functional Imaging During a Recognition Memory Task
Current Alzheimer Research Treatment of Periodontitis for the Prevention of Endothelial Dysfunction: A Narrative Review
Current Vascular Pharmacology Do Epigenetic Pathways Initiate Late Onset Alzheimer Disease (LOAD): Towards a New Paradigm
Current Alzheimer Research Microwave Assisted One-pot Three Component Synthesis of Novel 2-(5- Aryloxymethyl-1,3,4-thiadiazolo)-3-aryl-4-thiazolidinones
Letters in Organic Chemistry Relationship Between the Chemokine Receptor CCR5 and Microglia in Neurological Disorders: Consequences of Targeting CCR5 on Neuroinflammation, Neuronal Death and Regeneration in a Model of Epilepsy
CNS & Neurological Disorders - Drug Targets Fighting Alzheimer's Disease and Type 2 Diabetes: Pathological links and Treatment Strategies
CNS & Neurological Disorders - Drug Targets Synthesis and In vitro Evaluation of Thiadiazole Derivatives as AChE, Bu- ChE and LOX Inhibitors
Letters in Drug Design & Discovery The Kynurenine Pathway in the Acute and Chronic Phases of Cerebral Ischemia
Current Pharmaceutical Design Editorial: Ischemic Stroke Prevention
Current Vascular Pharmacology Antioxidant Pathways in Alzheimers Disease: Possibilities of Intervention
Current Pharmaceutical Design Insights into the Structure, Function, and Regulation of Human Cytochrome P450 1A2
Current Drug Metabolism Susceptibility of Periodontopathogenic and Cariogenic Bacteria to Defensins and Potential Therapeutic Use of Defensins in Oral Diseases
Current Pharmaceutical Design Adverse Events of Proton Pump Inhibitors: Potential Mechanisms
Current Drug Metabolism Creatine and the Liver: Metabolism and Possible Interactions
Mini-Reviews in Medicinal Chemistry P-gp Transporter and its Role in Neurodegenerative Diseases
Current Topics in Medicinal Chemistry The Use of Microarrays to Characterize Neuropsychiatric Disorders: Postmortem Studies of Substance Abuse and Schizophrenia
Current Molecular Medicine Hydrogen Sulphide in Heart and Systemic Circulation
Inflammation & Allergy - Drug Targets (Discontinued) Inflammatory Cytokines in Acute Ischemic Stroke
Current Pharmaceutical Design